Biomea Fusion Inc (BMEA)
11.00
-0.13
(-1.17%)
USD |
NASDAQ |
May 24, 16:00
11.01
+0.01
(+0.09%)
After-Hours: 20:00
Biomea Fusion Cash from Investing (TTM): -0.499M for March 31, 2024
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -0.499M |
December 31, 2023 | -2.22M |
September 30, 2023 | -2.913M |
June 30, 2023 | -2.649M |
March 31, 2023 | 5.143M |
December 31, 2022 | 27.34M |
September 30, 2022 | 32.59M |
Date | Value |
---|---|
June 30, 2022 | 32.29M |
March 31, 2022 | 25.60M |
December 31, 2021 | -33.36M |
September 30, 2021 | -37.94M |
June 30, 2021 | -37.88M |
March 31, 2021 | -38.56M |
December 31, 2020 | -0.051M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-38.56M
Minimum
Mar 2021
32.59M
Maximum
Sep 2022
-2.365M
Average
-1.360M
Median
Cash from Investing (TTM) Benchmarks
Poseida Therapeutics Inc | 67.55M |
Cartesian Therapeutics Inc | 5.883M |
BioXcel Therapeutics Inc | -0.02M |
NovaBay Pharmaceuticals Inc | 1.062M |
Palatin Technologies Inc | 9.41M |